Current perspectives of bispecific antibody-based immunotherapy

R. Talac, H. Nelson

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


The field of bispecific antibodies is an evolving field of research that has increasing clinical appeal. The fusion of two antibodies or antibody fragments introduced a new way to override natural specificity of T cell and induce effector responses against tumor targets in MHC-unrestricted manner. Initial experiences with bispecific antibodies demonstrate both the promise for and limitations of this anti-cancer strategy. Significant body of work has shown that bispecific antibodies have potential to induce T cell mediated anti-tumor responses in pre-clinical models. However, Immunotherapy with bispecific antibodies in humans has yet to prove its value in clinical settings. In addition, the production of high-quality bispecific antibodies for clinical applications, the optimal size and avidity of bispecific antibodies, and in vivo T cell pre-activation remain critical issues. In this review, we summarize recent progress in bispecific antibody-based immunotherapy and address essential aspects of this anti-cancer strategy.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalJournal of biological regulators and homeostatic agents
Issue number3
StatePublished - Jan 1 2001


  • Bispecific antibodies
  • Cancer
  • Immunotherapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Physiology
  • Immunology
  • Oncology
  • Endocrinology
  • Physiology (medical)
  • Cancer Research


Dive into the research topics of 'Current perspectives of bispecific antibody-based immunotherapy'. Together they form a unique fingerprint.

Cite this